As SGK1 appears to exert a broad and coordinated homeostatic response to maximize cell survival at different conditions, inhibition of SGK1, which also reduced its expression, seems to be an attractive strategy for therapeutic development in AD. This evidence concerns the gene SGK1 and Alzheimer disease.